As our immunohistochemical analysis demonstrated decreased chemo sensitivity of bladder cancer patients with lymph node invasion having low TFAP2α expression we investigated if TFAP2α silencing would render bladder cancer cells less prone to chemotherapy drugs. This evidence concerns the gene TFAP2A and urinary bladder cancer.